PetVivo (OTCPK:PETV) Q3 2026 Earnings call February 17, 2026 05:00 PM ET Company ParticipantsGarry Lowenthal - CFOJohn Dolan - Chief Business Development Officer and General CounselJohn Lai - CEOConference Call ParticipantsNone - AnalystJohn DolanGood afternoon, everyone. Thank you for joining us today to discuss our results for our third quarter and first nine months of fiscal 2026, ended December 31, 2025. Hosting our call today is our Chief Executive Officer, John Lai, and our Chief Financial Officer, Ga ...

PetVivo (OTCPK:PETV) Q3 2026 Earnings call February 17, 2026 05:00 PM ET Company ParticipantsGarry Lowenthal - CFOJohn Dolan - Chief Business Development Officer and General CounselJohn Lai - CEOConference Call ParticipantsNone - AnalystJohn DolanGood afternoon, everyone. Thank you for joining us today to discuss our results for our third quarter and first nine months of fiscal 2026, ended December 31, 2025. Hosting our call today is our Chief Executive Officer, John Lai, and our Chief Financial Officer, Ga ...

PetVivo (OTCPK:PETV) Q3 2026 Earnings call February 17, 2026 05:00 PM ET Speaker1Good afternoon, everyone. Thank you for joining us today to discuss our results for our third quarter and first nine months of fiscal 2026, ended December 31, 2025. Hosting our call today is our Chief Executive Officer, John Lai, and our Chief Financial Officer, Garry Lowenthal, as well as myself, John Dolan, PetVivo's Chief Business Development Officer and General Counsel. Following our remarks, we'll open the call to your que ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) Nevada 99-0363559 (State or other jurisdiction of ...

MINNEAPOLIS, MN, US, Feb. 17, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), and its wholly owned subsidiaries PetVivo Animal Health and PetVivo AI, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported financial and operational results for the third quarter and first nine months of its fiscal year 2026 ended December 31, 2025. The company will hold a conference call today at 5:00 p.m. Eastern time to di ...

MINNEAPOLIS, MN, US, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., in collaboration with its wholly-owned subsidiary PetVivo Animal Health (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, today announced that it is retracting and replacing its previously issued press release dated February 9, 2026 regarding the Company’s fiscal third quarter 2026 conference call. This press release supersedes in it ...

MINNEAPOLIS, MN, US, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc., including its wholly-owned subsidiary Petvivo Animal Health, Inc. (OTCQX: PETV; OTCID: PETVW), a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Monday, February 16, 2026 at 5:00 p.m. Eastern time to discuss results for the fiscal third quarter ended December 31, 2025. The financial results will be issued in a press release prior t ...

Core Insights - PetVivo Animal Health, Inc. has received formal acknowledgment from Health Canada for its product Spryng® with OsteoCushion® Technology as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy [1][2][3] Company Overview - PetVivo Holdings, Inc. operates as an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, leveraging human therapies for animal treatment in a capital-efficient manner [6][7] - The company has a robust pipeline of products, including Spryng® and PrecisePRP®, protected by twelve patents and six trade secrets [7] Product Details - Spryng is an intra-articular injectable device designed to support joint health and manage lameness and other joint-related issues in animals [2][4] - The product is currently available in the United States and through select international distribution partners, with plans for commercial availability in Canada anticipated in the second quarter of 2026 [4][3] Regulatory Milestone - The acknowledgment from Health Canada serves as an important endorsement of the company's scientific and regulatory strategy, reflecting its commitment to providing innovative solutions for animal health [3][4] - Despite the regulatory acknowledgment, Spryng is not expected to be immediately available in Canada due to ongoing infrastructure development and operational requirements [3]

Core Viewpoint - PetVivo Holdings, Inc. is actively participating in the DealFlow Discovery Conference scheduled for January 28-29, 2026, highlighting its commitment to engaging with investors and showcasing its innovations in medical devices and biomedical therapeutics for animals [1] Company Participation - The company will be represented by John Lai, the Chief Executive Officer, who will deliver a presentation and be available for one-on-one investor meetings during the conference [1]

Core Insights - PetVivo.ai has launched a video to explain its AI-powered platform for veterinary practices, aiming to simplify communication and enhance understanding of its services [1][2][4] - The platform connects pet parents with veterinary practices through a two-sided ecosystem, utilizing 10 specialized AI agents to facilitate client acquisition and health tracking [3][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, focusing on innovative medical devices and therapeutics for companion animals [8] - The company leverages human therapies for animal treatment, aiming for a quicker market entry compared to pharmaceuticals [8] - PetVivo has a diverse product pipeline, including patented technologies for managing joint-related afflictions in animals [9] Product and Service Details - The platform features a freemium model, starting with a free tier, to engage veterinary practices and pet parents [6] - Key products include SPRYNG with OsteoCushion technology for joint management and PrecisePRP, a platelet-rich plasma product for veterinary use [9]